FEED Validator

for Atom and RSS and KML

Congratulations!

This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

line 81, column 0: style attribute contains potentially dangerous content: max-height (5 occurrences) [help]
```
<ul class="wp-block-list">
```

Source: https://international-pharma.com/feed/

<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:atom="http://www.w3.org/2005/Atom"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
xmlns:media="http://search.yahoo.com/mrss/" >
<channel>
<title>International Pharmaceutical Industry</title>
<atom:link href="https://international-pharma.com/feed/" rel="self" type="application/rss+xml" />
<link>https://international-pharma.com</link>
<description>Peer Reviewed, Contemporary, Authoritative</description>
<lastBuildDate>Thu, 18 Sep 2025 12:52:06 +0000</lastBuildDate>
<language>en-GB</language>
<sy:updatePeriod>
hourly </sy:updatePeriod>
<sy:updateFrequency>
1 </sy:updateFrequency>
<generator>https://wordpress.org/?v=6.8.2</generator>
<image>
<url>https://international-pharma.com/wp-content/uploads/2022/01/Favicon-IPI-150x150.png</url>
<title>International Pharmaceutical Industry</title>
<link>https://international-pharma.com</link>
<width>32</width>
<height>32</height>
</image>
<item>
<title>CPHI Frankfurt Pharma Awards 2025 Finalists Announced</title>
<link>https://international-pharma.com/cphi-frankfurt-pharma-awards-2025-finalists-announced/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Thu, 18 Sep 2025 12:52:05 +0000</pubDate>
<category><![CDATA[News]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41666</guid>
<description><![CDATA[Hundreds of entries received across 14 categories showcasing innovation, sustainability, and leadership in pharma Informa Markets, has announced the shortlist for the CPHI Pharma Awards 2025, recognising outstanding achievements across pharmaceutical innovation, manufacturing, sustainability, leadership and women in pharma. The awards spotlight the companies and individuals pushing the boundaries of science and technology to advance […]]]></description>
<content:encoded><![CDATA[
Hundreds of entries received across 14 categories showcasing innovation, sustainability, and leadership in pharma
Informa Markets, has announced the shortlist for the CPHI Pharma Awards 2025, recognising outstanding achievements across pharmaceutical innovation, manufacturing, sustainability, leadership and women in pharma.
The awards spotlight the companies and individuals pushing the boundaries of science and technology to advance global healthcare.
The CPHI Pharma Awards finalists for 2025 include innovators redefining everything from synthetic biology and AI-powered formulation to patient access, circular packaging, and leadership in rare diseases, spotlighting the most transformative work happening in the industry today. This year’s shortlist also celebrates the next generation of pharmaceutical changemakers through the Future Leader and Women in Pharma categories, spotlighting individuals whose impact and vision are reshaping the industry from within.
“We’ve been incredibly impressed by the quality, originality, and ambition of this year’s submissions. Across every category, the finalists are setting new standards in pharmaceutical innovation, sustainability, and patient impact. The CPHI Pharma Awards are a vital platform to spotlight the progress shaping the future of our industry. We’re looking forward to celebrating these achievements and announcing the winners on the opening day of CPHI Frankfurt.” Tara Dougal, CPHI Event Director, Informa Markets.
The winners will be revealed during an exclusive networking reception on October 28 – the opening day of <a href="https://www.cphi.com/europe/en/home.html?utm_source=press-release&utm_medium=referral&utm_campaign=hln25cpw-cl-launch-release" target="_blank" rel="noopener">CPHI Frankfurt 2025</a>, held at Messe Frankfurt from October 28–30. 
<hr class="wp-block-separator has-alpha-channel-opacity"/>
Finalists by Category
The full list of 2025 finalists is available by category below. Further information on each finalist can be found <a href="https://www.cphi.com/europe/en/cphi-celebration/awards.html" target="_blank" rel="noopener">here</a>:
API Development and Innovation
<ul class="wp-block-list">
<li>Lonza: Design2Optimize(<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />)</li>
<li>CMAC: From Crystallisation to tablet: A scalable Platform for API Agglomeration.</li>
<li>Merck KgaA: mPredict Co-crystal Prediction Service</li>
<li>CordenPharma International: TAPS: TAG Assisted Peptide Synthesis. </li>
</ul>
Accelerating Innovation
<ul class="wp-block-list">
<li>NunaBio Ltd: Custom, cell-free, synthetic DNA</li>
<li>TriLink Biotechnologies: GMP-Grade CleanCap® M6 Analog</li>
<li>Covestro Deutschland AG: Mono-Material Drug Delivery Demonstrator</li>
<li>Accord Healthcare: Orgovyx – Transforming prostate cancer care</li>
<li>Invengene Private Limited: Room temperature-stable generic Posaconazole InjectionUsing Hydroxypropyl beta-cyclodextrin (HPβCD)</li>
<li>Prestige BioPharma: Ullenistamab: A Targeted MAB for pancreatic cancer. </li>
</ul>
At the Heart of Pharma
<ul class="wp-block-list">
<li>Accord Healthcare: A decade of impact with International Health Partners (IHP)</li>
<li>PharmEvo Pvt. Ltd: Elevating patient safety through intelligent design</li>
<li>Strides: Enhancing access to affordable healthcare – HIV</li>
<li>Farmak International: Resilient by Design: Farmak Group’s Ukrainian-rooted pharma network blueprint for crisis-proof global supply</li>
<li>CNX Therapeutics and the Social Mobility Foundation: Talent without barriers. </li>
</ul>
CEO of the Year
<ul class="wp-block-list">
<li>Bobby Sheng: Bora Pharmaceuticals</li>
<li>Deepak Bahri: Sentiss Pharma</li>
<li>Hanns-Christian Mahler: ten23 health</li>
<li>Lars Petersen: FUJIFILM Diosynth Biotechnologies</li>
<li>Lisa Soyeon Park: Prestige Biopharma</li>
<li>Michael Quirmbach: CordenPharma International. </li>
</ul>
Drug Delivery and Device Innovation
<ul class="wp-block-list">
<li>Azelis Group NV: Advanced Peristomal Barrier & Adhesion Cream </li>
<li>SHL Medical: Maggie® Mix: A dual-chamber autoinjector with Needle Isolation Technology (NIT®)</li>
<li>LTS Lohmann Therapie Systems AG: Launching the first biosimilar in an on-body injector</li>
<li>Ypsomed: Uniting sustainability and patient convenience in self-injection devices. </li>
</ul>
Finished Formulation
<ul class="wp-block-list">
<li>Zerion Pharma A/S: Dispersome® technology</li>
<li>Evonik Industries AG: EUDRACAP® colon: The world’s first functional ready-to-fill capsule for oral drug delivery to target the ileo-colonic region</li>
<li>CrystecPharma: Modified Supercritical Anti-Solvent (mSAS®) particle engineering for stabilisation of biomolecules</li>
<li>Roquette: ReadiLYCOAT® Plant-Based Coating Systems for enhanced oral dosage solutions</li>
<li>Lonza Capsules & Health Ingredients: Innovaform® Innovation and formulation accelerator. </li>
</ul>
Future Leader
<ul class="wp-block-list">
<li>Jakub Knurek: Mabion</li>
<li>Mark Kelada: Nelipak Laboratory Services</li>
<li>Mohammad Farahani: CinnaGen</li>
<li>Yolanda Gomez: Esteve CDMO</li>
<li>Yuvansh Khokhani:YSK Laboratories Pvt Ltd. </li>
</ul>
Manufacturing Excellence
<ul class="wp-block-list">
<li>Coriolis Pharma Research GmbH: Advanced lyophilization modelling</li>
<li>Enzene: EnzeneX<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />: Fully-connected continuous manufacturing<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /></li>
<li>Bausch+Ströbel SE + Co. KG: GENEX, robotic, modular aseptic fill-finish platform</li>
<li>VectorBuilder: VectorBuilder’s gene drug manufacturing platform. </li>
</ul>
Packaging and Machinery
<ul class="wp-block-list">
<li>SCHOTT Pharma: SCHOTT TOPPAC® infuse – the next generation IMA LIFE: TILE-X: New generation gloveless aseptic fill-finish system</li>
<li>H&T Presspart: Vytal® innovative RTU snap-fit closure.</li>
</ul>
 Start-Up Initiative
<ul class="wp-block-list">
<li>Green Elephant Biotech: CellScrew®</li>
<li>NunaBio Ltd: Custom: Cell-free, synthetic DNA – including high complexity sequences, multi kilobase length and milligram scale – made in days to weeks</li>
<li>NovoArc GmbH: Lipids for innovative drug formulation</li>
<li>ORYL Photonics: ORYL F1.</li>
</ul>
 Supply Chain Excellence
<ul class="wp-block-list">
<li>Cryoport Systems: Integrated end-to-end supply chain platform</li>
<li>Occam Systems: Resilient chemical supply chains, supercharged by AI</li>
<li>QYOBO GmbH: QYOBO platform</li>
<li>TraceLink: TraceLink Orchestration Platform for Universal Solutions (OPUS). </li>
</ul>
Sustainability
<ul class="wp-block-list">
<li>Celtic Renewables: Leading the Green Chemical Revolution, transforming industrial by-products into high-value green chemicals.</li>
<li>Enantios: Enantios platform – Enabling fast, label-free chiral analysis in solution</li>
<li>Avantor: J.T.Baker® Viral Inactivation Solution – Environmentally safer detergent for virus removal in bioprocessing</li>
<li>AustinPx: KinetiSol<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Technology, a solvent-free, fusion-based technology that transforms poorly soluble drugs into high-bioavailability formulations</li>
<li>Kindeva: Leading the way in next-generation propellants (NGPs) -commercial-ready capabilities in HFA152a and HFO1234ze propellants.</li>
<li>Alliance to Zero: Lean, Green and Secure, aregulatory-ready, blister-free, syringe solution</li>
<li>Huhtamaki: Omnilock<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Ultra PAPER</li>
<li>Botanical Solution Inc. (BSI): Sustainability Grows on Trees: Producing QS-21, the Gold Standard vaccine adjuvant. </li>
</ul>
Woman of the Year
<ul class="wp-block-list">
<li>Adriana Kiędzierska-Mencfeld, Polpharma Biologics</li>
<li>Christiane Bardroff, Rentschler Biopharma</li>
<li>Dr. Ivy Gao, Sunresin </li>
<li>Jennifer Gattari, Pfizer CentreOne</li>
<li>Jonina Gudmundsdottir, Coripharma</li>
<li>Meeta Gulyani, Ecolab Life Sciences.</li>
</ul>

 About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate, and grow. As part of Informa PLC, it delivers more than 450 B2B events annually across key sectors including healthcare, life sciences, construction, and fashion. The company’s mission is to foster global communities, enabling meaningful connections and commercial success.
<h3 class="wp-block-heading"><a></a>To learn more about CPHI Frankfurt, visit the website <a href="https://www.cphi.com/europe/en/home.html" target="_blank" rel="noopener">here</a> </h3>
<h3 class="wp-block-heading"></h3>

]]></content:encoded>
</item>
<item>
<title>The Future of Aseptic Manufacturing: An interview with Marcel Weizel, Business Development Manager at Bausch+Ströbel</title>
<link>https://international-pharma.com/the-future-of-aseptic-manufacturing-an-interview-with-marcel-weizel-business-development-manager-at-bauschstrobel/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:56:18 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41661</guid>
<description><![CDATA[With GENEX, a new generation of robotic systems is transforming pharmaceutical production. The implementation of fully automated processes is setting new benchmarks for product and operator safety, operational flexibility, and cost efficiency. In this interview, Marcel Weizel, an industry expert, explains how these innovations are reshaping cleanroom manufacturing and why Annex 1 plays a decisive […]]]></description>
<content:encoded><![CDATA[

With GENEX, a new generation of robotic systems is transforming pharmaceutical production. The implementation of fully automated processes is setting new benchmarks for product and operator safety, operational flexibility, and cost efficiency. In this interview, Marcel Weizel, an industry expert, explains how these innovations are reshaping cleanroom manufacturing and why Annex 1 plays a decisive role.
Robot-assisted cleanroom production has been central to pharmaceutical manufacturing for some time. How does the new GENEX system go beyond traditional automation?
Marcel Weizel: GENEX represents a fundamental shift. While robots have long been used for handling packaging materials, GENEX extends their role to critical tasks such as automated product path installation, bio- and surface-monitoring, and even troubleshooting. These functions, which previously required manual glove interventions, are now performed fully automatically. This not only increases safety and quality but also reduces cost per unit, making advanced therapies more accessible to patients.
Why is this development so important for today’s pharmaceutical industry?
Marcel Weizel: The industry is moving toward smaller and more flexible batch sizes. Large-scale systems have historically facilitated widespread availability of drugs such as insulin. Today’s challenge lies in the ongoing development of specialised therapies, including orphan drugs and cell and gene therapies, which are manufactured in smaller quantities. GENEX is designed specifically for this environment. Its modular design allows manufacturers to adapt process chains to individual requirements while ensuring rapid and compliant setup changes.

]]></content:encoded>
</item>
<item>
<title>Mushroom Supplements: Health Trends and Regulatory Environment</title>
<link>https://international-pharma.com/mushroom-supplements-health-trends-and-regulatory-environment/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:51:46 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41658</guid>
<description><![CDATA[The mushroom supplement market in the UK has experienced remarkable growth in recent years, evolving from a niche segment to a mainstream category. This expansion has been driven by increased consumer interest in natural health and wellness products, functional foods, and plant-based trends. In 2023, the UK mushroom market generated revenue of USD 1,271.5 million, […]]]></description>
<content:encoded><![CDATA[

The mushroom supplement market in the UK has experienced remarkable growth in recent years, evolving from a niche segment to a mainstream category. This expansion has been driven by increased consumer interest in natural health and wellness products, functional foods, and plant-based trends. In 2023, the UK mushroom market generated revenue of USD 1,271.5 million, and it is projected to nearly double by 2030, reaching USD 2,513.0 million, with ongoing expansion anticipated.¹
Mushroom supplements are botanical dietary products derived from various species of medicinal and functional mushrooms. They are available in multiple forms, including whole mushrooms, extracts, powders, and capsules. Common species include reishi (Ganoderma lucidum), lion’s mane (Hericium erinaceus), chaga (Inonotus obliquus), and cordyceps (Cordyceps sinensis). These supplements may be offered as single-ingredient products or blended with other botanicals, vitamins, or minerals. They are valued for their purported health benefits, which range from boosting immunity and enhancing cognitive function to supporting energy levels and reducing stress.
The use of medicinal mushrooms is not new. In Traditional Chinese Medicine (TCM) and other ancient healing systems, mushrooms have been used for centuries for their immune-boosting, anti-inflammatory, and adaptogenic properties. What distinguishes the current trend is the convergence of ancient wisdom with modern scientific investigation. Research has isolated bioactive compounds—such as beta-glucans, terpenoids, and polysaccharides—that are believed to drive many of the health benefits. These compounds are now the focus of clinical studies exploring their effects in humans.²

]]></content:encoded>
</item>
<item>
<title>Navigating Compliance and Regulatory Readiness with Medical Information</title>
<link>https://international-pharma.com/navigating-compliance-and-regulatory-readiness-with-medical-information/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:49:04 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41655</guid>
<description><![CDATA[Post-market regulations have grown significantly more complex over time. As pharmaceutical products reach broader and more diverse populations, the risk of off-label use or misuse increases. Additionally, navigating local regulatory nuances, cultural differences, and varying healthcare practices has become increasingly difficult. These challenges are particularly acute during global expansion efforts, where mid-sized pharmaceutical companies often […]]]></description>
<content:encoded><![CDATA[

Post-market regulations have grown significantly more complex over time. As pharmaceutical products reach broader and more diverse populations, the risk of off-label use or misuse increases. Additionally, navigating local regulatory nuances, cultural differences, and varying healthcare practices has become increasingly difficult. These challenges are particularly acute during global expansion efforts, where mid-sized pharmaceutical companies often struggle due to limited resources and a lack of in-house expertise needed to meet diverse regulatory and operational requirements.
No single internal team can be expected to stay current with every regional law, cultural expectation, and evolving technology on their own. This is where a trusted Medical Information (MI) partner becomes invaluable. MI teams play a critical role in helping companies remain compliant while ensuring that scientific information is shared appropriately. This article outlines the key operational areas where pharmaceutical companies must maintain regulatory compliance and highlights how MI can serve as a compliant hub for scientific exchange with healthcare professionals and the public.
<h4 class="wp-block-heading">Regulatory Frameworks Around the Globe</h4>
Pharmaceutical companies operating across international markets must stay aligned with each region’s unique expectations. These include stringent rules related to data protection, marketing practices, digital transparency, and safety communication. The complexity of these overlapping regulatory frameworks presents a significant compliance challenge for organisations—particularly as digital engagement and real-time information exchange increase.
MI teams can provide vital support in managing these challenges. By acting as centralised, trained, and compliant points of contact, MI can ensure that scientific and safety information is communicated accurately and responsibly. In doing so, they help bridge the gap between regulatory obligations and real-world communication needs, allowing pharmaceutical companies to expand responsibly while protecting patients and preserving trust.
]]></content:encoded>
</item>
<item>
<title>Intranasal Insulin for Alzheimer’s: Advancing Brain-Targeted Delivery</title>
<link>https://international-pharma.com/intranasal-insulin-for-alzheimers-advancing-brain-targeted-delivery/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:46:16 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41652</guid>
<description><![CDATA[Alzheimer’s disease (AD) represents a growing public health concern. While earlier estimates placed global dementia prevalence at around 50 million people, more recent evidence suggests that some form of AD may affect as many as 416 million individuals worldwide.¹ With increasing life expectancy and an ageing global population, this number is expected to rise even […]]]></description>
<content:encoded><![CDATA[

Alzheimer’s disease (AD) represents a growing public health concern. While earlier estimates placed global dementia prevalence at around 50 million people, more recent evidence suggests that some form of AD may affect as many as 416 million individuals worldwide.¹ With increasing life expectancy and an ageing global population, this number is expected to rise even further in the coming decades, placing significant pressure on healthcare infrastructure and families.¹,²
<h5 class="wp-block-heading">Growing Need for Multidisciplinary Treatment</h5>
Despite decades of research and global efforts to find a cure, treatment options for AD remain limited.³,⁴ The amyloid cascade hypothesis—which implicates the accumulation of amyloid proteins in and around brain cells as the primary cause of AD—has long shaped the direction of therapeutic research.⁵ This has led to the development of anti-amyloid antibodies, some of which have received regulatory approval in the United States for their ability to reduce plaque burden and modestly slow disease progression.⁶
However, clinical trials have often produced mixed results, with many therapies showing limited effects on improving cognitive symptoms.³,⁴,⁶ Additionally, not all individuals diagnosed with AD exhibit significant plaque accumulation, while some people with substantial amyloid deposits show no measurable cognitive decline.⁴ This discrepancy has prompted growing scepticism about the clinical value of amyloid clearance as a singular therapeutic target. An increasing body of evidence now supports the view that AD is not a uniform disease, but a multifactorial syndrome. Contributing mechanisms may include insulin resistance, hormonal changes, vascular dysfunction, and chronic inflammation.⁴,⁵ This evolving understanding is driving a shift toward more comprehensive, multidisciplinary treatment strategies that address the broader complexity of the condition.

]]></content:encoded>
</item>
<item>
<title>Mapping the Proteome to Understand the Complexity of Neurodegenerative Diseases</title>
<link>https://international-pharma.com/mapping-the-proteome-to-understand-the-complexity-of-neurodegenerative-diseases/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:42:30 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41649</guid>
<description><![CDATA[Neurological conditions have emerged as the leading global cause of illness and disability, impacting more than 3 billion people.¹ Among these, neurodegenerative diseases stand out for their relentless progression, lack of curative treatments, and their rising prevalence within aging populations. In particular, Alzheimer’s disease is known for its slow onset and progressive deterioration, and the […]]]></description>
<content:encoded><![CDATA[

Neurological conditions have emerged as the leading global cause of illness and disability, impacting more than 3 billion people.¹ Among these, neurodegenerative diseases stand out for their relentless progression, lack of curative treatments, and their rising prevalence within aging populations. In particular, Alzheimer’s disease is known for its slow onset and progressive deterioration, and the lack of a cure underscores the critical need to deepen our understanding of the molecular cues that lead to neurodegeneration, with the goal of identifying effective preventative and therapeutic measures.
Neurodegenerative diseases like Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and Huntington’s are all characterised by disrupted proteome homeostasis and selective neuronal loss. These conditions have become a significant burden for an ageing society, with one-third of people in industrialised nations expected to develop a neurodegenerative disease during their lifetime.¹ Their extended disease courses, progressive deterioration, and necessity for long-term care underscore the urgency of understanding the molecular mechanisms driving neurodegeneration.
Mass spectrometry (MS)-based proteomics serves as a powerful window into neurodegeneration, enabling researchers to comprehensively analyse changes in protein abundance, modifications, interactions, and degradation pathways. A key advance of this approach is the study of proteoforms—the structurally and functionally diverse protein variants derived from the same gene as a result of genetic variation, alternative splicing, and post-translational modifications (PTMs). Investigating proteoforms sheds new light on protein function and dysfunction within neurodegenerative disease contexts and is crucial for resolving complex disease mechanisms.
]]></content:encoded>
</item>
<item>
<title>Advancements in Neuromodulation: A New Era for Respiratory Health</title>
<link>https://international-pharma.com/advancements-in-neuromodulation-a-new-era-for-respiratory-health/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:40:13 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41646</guid>
<description><![CDATA[Neuromodulation is an approach that involves the use of devices to normalise or modulate nerve activity through the targeted delivery of electrical stimuli. Electrical stimuli can be delivered either invasively through surgical implantation of the device under the skin or non-invasively through the external application of a device to the skin. Applications for neuromodulation are […]]]></description>
<content:encoded><![CDATA[

Neuromodulation is an approach that involves the use of devices to normalise or modulate nerve activity through the targeted delivery of electrical stimuli. Electrical stimuli can be delivered either invasively through surgical implantation of the device under the skin or non-invasively through the external application of a device to the skin. Applications for neuromodulation are increasing and include the use of deep brain stimulation (DBS) for Parkinson’s disease and essential tremor, vagus nerve stimulation (VNS) for refractory epilepsy and depression, and transcutaneous electrical nerve stimulation (TENS) for menstrual cramps. These devices are already utilised widely, with an estimated 244,000 DBS devices implanted and 125,000 patients receiving VNS therapy worldwide.¹,²
With a broad therapeutic scope and numerous ongoing active clinical trials involving neuromodulation devices, the neuromodulation market is poised for significant growth in the coming decade. According to a recent report by Markets and Markets, the global neuromodulation device industry was valued at $5.6 billion in 2022 and is expected to reach $11 billion by 2028.³ Another emerging therapeutic application for neuromodulation, which will contribute to this growth, is the treatment of respiratory conditions. Neuromodulation techniques, which can target neural pathways involved in respiratory function, can be used as an adjunct to more conventional treatments and are already being used to improve respiratory symptoms.
Neuromodulation for Respiratory Health
Respiratory conditions are estimated to affect 16.8 million people and are responsible for 136,000 deaths each year in the UK alone.⁴ Breathlessness, commonly referred to as dyspnoea, is a common feature of many respiratory conditions, including chronic obstructive pulmonary disease (COPD) and pulmonary hypertension. Dyspnoea can be highly disabling and have a significant impact on a sufferer’s ability to perform daily activities and their quality of life. Management of dyspnoea typically involves a combination of pharmacological drugs, pulmonary rehabilitation, and oxygen therapy. However, these treatments often lack efficacy, with one study finding that 53% of COPD patients still experience severe and persistent dyspnoea despite optimum inhaled medication and pulmonary rehabilitation.⁵

]]></content:encoded>
</item>
<item>
<title>Advancing Clinical Development Through Autoinjectors: Enabling Patient-Centric Drug Delivery</title>
<link>https://international-pharma.com/advancing-clinical-development-through-autoinjectors-enabling-patient-centric-drug-delivery/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:36:49 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41643</guid>
<description><![CDATA[The biopharmaceutical industry is continually seeking innovative solutions that can improve drug delivery, strengthen patient compliance, and optimise therapeutic outcomes. Among the most significant advancements in this regard are autoinjectors, which have emerged as pivotal technologies in the evolving landscape of injectable therapies. Their earlier adoption into clinical trials highlights their potential to transform drug […]]]></description>
<content:encoded><![CDATA[

The biopharmaceutical industry is continually seeking innovative solutions that can improve drug delivery, strengthen patient compliance, and optimise therapeutic outcomes. Among the most significant advancements in this regard are autoinjectors, which have emerged as pivotal technologies in the evolving landscape of injectable therapies. Their earlier adoption into clinical trials highlights their potential to transform drug delivery systems, yet their successful integration is not without challenges. To realise the full promise of these devices, sponsors must adopt a strategic approach that addresses issues of design, drug compatibility, regulatory requirements, patient usability, and long-term scalability.
From Vials to Patient-Centric Devices Traditionally, clinical trials—particularly in early-phase studies—relied on vials as the primary container for intravenous administration. These formats offered flexibility in fill volumes and dosages, aligning with the early objectives of establishing proof of concept, demonstrating safety, and determining tolerated doses. However, the industry’s increasing emphasis on patient-centricity has reshaped these conventions. With more therapies aimed at chronic conditions and rare diseases, self-administration has become an expectation rather than an exception.
Prefilled syringes, needle safety devices, and autoinjectors have therefore become integral to product portfolios. For patients, they promise ease of use, reduced injection anxiety, and greater independence. For sponsors, they deliver advantages in compliance, trial retention, and data quality. The market for autoinjectors is also being propelled by device innovation, as manufacturers improve ergonomics, expand compatibility with high-viscosity biologics, and explore connectivity features that can capture adherence data. Importantly, introducing autoinjectors during the clinical trial phase rather than waiting until commercialisation provides sponsors with valuable insights into real-world use scenarios while also accelerating the path to market readiness.
]]></content:encoded>
</item>
<item>
<title>Back to Basics: What Will Drug Safety Look Like in 5–10 Years?</title>
<link>https://international-pharma.com/back-to-basics-what-will-drug-safety-look-like-in-5-10-years/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:33:52 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41640</guid>
<description><![CDATA[It’s understandable that regulators’ extensive demands and internal budget pressures have rendered pharmacovigilance primarily a compliance and risk management activity. But strategies now need to be revised – so that the drive to better serve patients is reinstated as the primary mission, says Lucinda Smith, Chief Safety Product Officer at ArisGlobal. Between 2020 and 2022, […]]]></description>
<content:encoded><![CDATA[

It’s understandable that regulators’ extensive demands and internal budget pressures have rendered pharmacovigilance primarily a compliance and risk management activity. But strategies now need to be revised – so that the drive to better serve patients is reinstated as the primary mission, says Lucinda Smith, Chief Safety Product Officer at ArisGlobal.
Between 2020 and 2022, as the COVID-19 pandemic peaked, the role of drug safety attracted unprecedented mainstream attention. As new vaccines entered the market and a range of treatments were applied, entire generations gained new appreciation of side-effects at scale, and of the fundamental assumption that the products they take are “safe”.
The ability to quickly and efficiently capture accurate data, spot trends, draw robust conclusions about emerging safety issues, and act on them promptly was tangible and expected by the public. Yet the pharma industry largely missed this opportunity to more permanently reframe pharmacovigilance (PV) and its place in the drug development cycle.
From Caution to Controlled Extension of Opportunity
That the core remit of drug safety is to ensure optimal outcomes for patients has been overshadowed by the rising expectations of regulators over the last couple of decades. This has contributed to the function assuming “cost centre” status, and therefore a target for significant streamlining – the goal being to enable the absorption of increasing workloads (most notably around adverse event–AE–case processing) without adding costs.
]]></content:encoded>
</item>
<item>
<title>AI-Augmented Innovation in Drug Discovery</title>
<link>https://international-pharma.com/ai-augmented-innovation-in-drug-discovery/</link>
<dc:creator><![CDATA[Alice Phillips]]></dc:creator>
<pubDate>Wed, 17 Sep 2025 17:31:55 +0000</pubDate>
<category><![CDATA[Current Features]]></category>
<category><![CDATA[Volume 17, Issue 3]]></category>
<guid isPermaLink="false">https://international-pharma.com/?p=41637</guid>
<description><![CDATA[nnovators in pharma/biopharma seek to implement systems that support the discovery, development, and commercial launch of new products. Of particular interest are systems to support the implementation of continuous and mutually reinforcing digital-physical feedback loops. Here, digital tools and methods enhance physical processes, and feedback from these improved physical processes informs progressive digital advancements. In […]]]></description>
<content:encoded><![CDATA[

nnovators in pharma/biopharma seek to implement systems that support the discovery, development, and commercial launch of new products. Of particular interest are systems to support the implementation of continuous and mutually reinforcing digital-physical feedback loops. Here, digital tools and methods enhance physical processes, and feedback from these improved physical processes informs progressive digital advancements.
In traditional, non-digitalised drug discovery Design, Make, Test, and Analyse (DMTA) cycles, each transition between stages often demands substantial human effort to transpose and translate information, bridging disparate systems and domain-specific knowledge. Inefficient management of these transitions can result in productivity loss, as practitioners must frequently consult subject matter experts to translate critical, context-dependent information from design platforms to execution and analysis systems. This reliance on manual processes also increases the risk of transposition or transcription errors, where inaccurate transfer of numerical or textual data into digital interfaces may lead to failed experiments, flawed interpretations, or misguided decisions.
Introducing modern AI-powered tools into the DMTA workflow not only streamlines these transitions but also enhances the analysis phase: advanced algorithms can rapidly process experimental data; uncover patterns that might escape human notice; and generate actionable insights. To ensure that learnings are preserved and accessible for future cycles, results from such AI-enabled analyses should be systematically documented within integrated digital repositories, allowing teams to memorialise findings, trace decisions, and enable continual refinement of the DMTA cycle. By minimising manual intervention and harnessing AI’s analytical capabilities, organisations foster a virtuous, resilient DMTA loop that seamlessly connects digital and physical domains.
]]></content:encoded>
</item>
</channel>
</rss>

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):

<a href="http://www.feedvalidator.org/check.cgi?url=https%3A//international-pharma.com/feed/"><img src="valid-rss-rogers.png" alt="[Valid RSS]" title="Validate my RSS feed" /></a>

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=https%3A//international-pharma.com/feed/

Home · About · News · Docs · Terms